FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma

Authors

  • Seo Hee Choi,

    1. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
    • S.H.C and J.S.C contributed equally to this work as co-first authors.
  • Jee Suk Chang,

    1. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
    • S.H.C and J.S.C contributed equally to this work as co-first authors.
  • Yong Hyu Jeong,

    1. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Youngin Lee,

    1. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Mijin Yun,

    1. Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Jinsil Seong

    Corresponding author
    1. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea
    • Correspondence: Jinsil Seong, MD, PhD, Department of Radiation Oncology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea

      Tel: +82-2-2228-8095

      Fax: +82-2-312-9033

      e-mail: jsseong@yuhs.ac

    Search for more papers by this author

  • This research was presented at 55th Annual Meeting of the American Society of Radiation Oncology (ASTRO), September 22-25, 2013, Atlanta.

Abstract

Aims

To determine the utility of FDG-PET in predicting long-term infield tumour control after RT in patients with metastatic hepatocellular carcinoma (HCC) to bone.

Methods

Among 223 patients with HCC skeletal metastases diagnosed, we reviewed 22 patients with 45 total sites treated with RT who had at least two FDG-PETs prior to and after RT. The median RT dose was 42 Gy (range, 22–48) with a median fraction of 3 Gy (range, 2–8). Helical tomotherapy was generally offered for lesions that received higher RT dose (36%). The intrahepatic control rate in all patients was 73% at the time of referral. The ratio of tumour SUV to blood-pool activity SUV (SUV-ratio) was calculated. The primary end-points were infield progression-free survival (infield-PFS) and infield event-free survival (infield-EFS; recurrent and intractable pain or skeletal-related events).

Results

Among 45 sites, 20 had tumour progression and 21 developed events in the previously treated area. A higher SUV-ratio before RT, SUV-ratio decline and higher radiation dose were independently and significantly correlated with better infield-PFS (both < 0.05). The tumours with a pre-RT SUV-ratio ≥3.0 and SUV-ratio decline ≥40% had significantly better infield-PFS and EFS than those with either a pre-RT SUV-ratio <3.0 or SUV-ratio decline <40% (both < 0.05).

Conclusions

FDG-PET may help to predict outcomes of infield tumour control following palliative RT for treatment of HCC bone metastases. Tumours with low metabolic uptake before RT or with a minor decline in post-RT SUV-ratio showed poor long-term infield tumour control.

Ancillary